Inhatarget Therapeutics is a ULB spin-off company dedicated to the early development of innovative treatments by inhalation of severe and/or chronic respiratory diseases, with a first focus on lung cancer.
Inhatarget Therapeutics is currently focusing its activities on the development of its lead product (innovative formulation of cisplatin as a dry powder for inhalation) and the structuration of a pipeline of inhalation products. The main activities of the company are CMC lab-scale, tech transfer and industrial scale-up, preclinical studies (in vitro and in vivo) of efficacy, pharmacokinetics and toxicity, as well as the design and management of a clinical study.
Contact
Frédéric De Coninck
CEO
Frederic.de.coninck@inhatarget.com
+32(0)484.71.37.73
